Gregory Madden is an Infectious Disease physician affiliated with University of Virginia Health System. OpenAlex indexes 70 publications with 517 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1215 Lee St
Charlottesville, VA 229085400
Telephone
434-924-3627Provider last certified this registry record 31 Jul 2021.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Aimmune Therapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%First-generation cephalosporins100%Cefadroxil100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Immune profiling to stratify Clostridioides difficile infection outcomes
University of Virginia
FY2025$192,201K23AI163368 - Immune profiling to stratify Clostridioides difficile infection outcomes
University of Virginia
FY2024$192,201K23AI163368 - Immune profiling to stratify Clostridioides difficile infection outcomes
University of Virginia
FY2023$192,201K23AI163368
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P-1568. B-cell Depletion via Anti-CD20 Does Not Increase Recurrent Clostridioides difficile Infection Risk
Open Forum Infectious Diseases
2026 - Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia
Annals of Clinical Microbiology and Antimicrobials
2025 - IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity
Journal of Clinical Investigation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Frederick Hayden, MD
University of Virginia Health System
Allan Tsung, MD
University of Virginia Health System
Irving Kron, MD
University of Virginia Health System
Karen Ballen, MD
University of Virginia Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”